• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Israel·Healthcare·IRME
Share

IR-Med Inc. Stocks

$ 0Last Updated 30.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 204493

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

IR-Med Inc. is an emerging medical technology firm dedicated to developing advanced diagnostic and medical solutions by leveraging a platform that integrates infra-red light spectroscopy with artificial intelligence. The company's product pipeline includes PressureSafe, a handheld optical monitoring device engineered for the early identification of pressure-induced tissue damage in the skin and subcutaneous layers, often resulting from extended periods of patient immobility. Additionally, IR-Med is developing Nobiotics, an innovative otoscope designed to provide medical professionals with immediate feedback on the presence of middle ear infections (Otitis Media), a prevalent condition among pediatric patients. IR-Med Inc. operates from its headquarters in Rosh Pina, Israel.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.11.2026 16:18

Morning in New York: The High-Tech Sector Cools Off Ahead of the Election

02.11.2026 16:04

"I know he's an idiot": Ryanair CEO assesses the business benefits of his feud with Musk

02.11.2026 15:50

A "Cleaning-Out" Pullback: Morgan Stanley Suggests Entering the Market Ahead of a Rally to 8,000 Points

02.11.2026 15:10

"Some People Might Get Nervous": What Lies Ahead for the Tenge and Investors in Kazakh Bonds

02.11.2026 13:46

Goldman Sachs has raised its oil price forecast for 2027. What risks does the bank see?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026